B

Bergenbio ASA
OSE:BGBIO

Watchlist Manager
Bergenbio ASA
OSE:BGBIO
Watchlist
Price: 11.8 NOK -5.9% Market Closed
Market Cap: 479.2m NOK
Have any thoughts about
Bergenbio ASA?
Write Note

Bergenbio ASA
Total Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Bergenbio ASA
Total Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Assets CAGR 3Y CAGR 5Y CAGR 10Y
B
Bergenbio ASA
OSE:BGBIO
Total Assets
kr194.7m
CAGR 3-Years
-28%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
Hofseth Biocare ASA
OSE:HBC
Total Assets
kr365.3m
CAGR 3-Years
-6%
CAGR 5-Years
2%
CAGR 10-Years
5%
L
Lytix Biopharma AS
OSE:LYTIX
Total Assets
kr63.9m
CAGR 3-Years
25%
CAGR 5-Years
2%
CAGR 10-Years
N/A
Arcticzymes Technologies ASA
OSE:AZT
Total Assets
kr341.8m
CAGR 3-Years
9%
CAGR 5-Years
35%
CAGR 10-Years
12%
N
Nykode Therapeutics ASA
OSE:NYKD
Total Assets
$179.9m
CAGR 3-Years
-5%
CAGR 5-Years
36%
CAGR 10-Years
N/A
T
Thor Medical ASA
OSE:TRMED
Total Assets
kr320.1m
CAGR 3-Years
-14%
CAGR 5-Years
-9%
CAGR 10-Years
18%
No Stocks Found

Bergenbio ASA
Glance View

Market Cap
461.2m NOK
Industry
Biotechnology

BerGenBio ASA engages in the development of biopharmaceutical product for cancer therapy. The company is headquartered in Bergen, Hordaland. The company went IPO on 2017-04-07. The firm's business portfolio comprises such development stage products as oral axillary lymphoscintigraphy (AXL) kinase inhibitors, small molecule AXL inhibitors, and antibody programs. Its flagship product is BGB324, an orally avaliable small molecule AXL kinase inhibitor. Inhibition of AXL kinase activity addresses an important mechanism in the evolution of cancer cell in terms of its aggressiveness, and focuses on creation of therapeutic options for cancer patients. The firm also performs a range of clinical trials for interested patients, primarily affected with acute myeloid leukemia and non-small cell lung cancer.

BGBIO Intrinsic Value
0.2 NOK
Overvaluation 98%
Intrinsic Value
Price
B

See Also

What is Bergenbio ASA's Total Assets?
Total Assets
194.7m NOK

Based on the financial report for Sep 30, 2024, Bergenbio ASA's Total Assets amounts to 194.7m NOK.

What is Bergenbio ASA's Total Assets growth rate?
Total Assets CAGR 5Y
-9%

Over the last year, the Total Assets growth was 4%. The average annual Total Assets growth rates for Bergenbio ASA have been -28% over the past three years , -9% over the past five years .

Back to Top